Ocular endpoints can become a failure point in otherwise well-designed clinical trials. When IOP measurements vary across sites, OCT imaging is not captured consistently, or BCVA assessments are not...
Read More
Key Takeaways A failed OCT scan in retina clinical trials does not just cost a rescan. It costs a visit window, a deviation filing, and sometimes the patient. The invoice never shows full damage....
Read More
In ophthalmic trials supported by 20/20 Onsite, point-of-need delivery has achieved a 9% dropout rate against a 30% Phase 3 industry benchmark, a 70% improvement in retention. Participants receiving...
Read More
In clinical trials that deal with ocular hypertension, intraocular pressure (IOP) is not just a measurement. It is often the primary determinant of regulatory credibility and treatment response...
Read More
Selecting an ophthalmology CRO is a risk decision, not just a vendor decision: sponsors are choosing how ocular endpoints will be protected across every site and visit. Most ophthalmology CROs...
Read More
Ophthalmology Clinical Trials: Strategic Growth, Scientific Innovation, and Execution Risk for Sponsors Key Takeaways Aging populations and chronic disease growth are expanding the patient pool for...
Read More
Transportation is not a soft, patient-experience issue in clinical trials. It's a protocol execution risk. When participants miss visits because getting to the site is difficult, timelines slip, data...
Read More
How to Reduce Patient Dropout Rates in Clinical Trials: Sponsor-Driven Retention Strategies That Protect Timelines Key Takeaways Dropout is a sponsor risk that impacts timelines, data continuity,...
Read More